期刊文献+

UDCA联合异甘草酸镁治疗Ⅱ、Ⅲ期原发性胆汁性肝硬化患者的临床疗效观察 被引量:5

The clinical effect of UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis
暂未订购
导出
摘要 目的探讨熊去氧胆酸(UDCA)联合异甘草酸镁对早中期原发性胆汁性肝硬化(PBC)患者的临床疗效。方法选择我院收治的53例PBC患者,随机分为治疗组(28例)和对照组(25例),治疗组给予UDCA联合异甘草酸镁,对照组单独给予UDCA;比较两组患者临床症状改善和患者免疫指标水平变化情况。结果治疗后治疗组血清TBil、AST、ALT、γ-GGT、ALP均明显低于对照组(P<0.05);治疗组治疗4周后总有效率为82.14%,对照组为60.87%,治疗组显著高于对照组,两组相比差异具有统计学意义(χ2=11.102,P=0.000)。治疗后两组患者免疫指标均显著降低,其中治疗组各免疫指标降低水平显著优于对照组,两组间相比差异具有统计学意义(P<0.05)。结论 UDCA联合异甘草酸镁治疗Ⅱ、Ⅲ期PBC患者可以显著改善患者的临床症状,提高临床疗效,且不良反应轻微,可以考虑作为PBC的治疗方法之一。 Objective To observe the clinical effect of UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis (PBC) and to analyze the immune index levels changes.Methods Fiftythree patients with PBC in our hospital were randomly divided into the treatment group and control group,the treatment group received UDCA combined with Magnesium isoglycyrrhizinate,while the control group was only given UDCA.The clinical symptoms and the changes of immunological indexes were compared between two groups.Results The levels of serum TBil,AST,ALT,γ-GGT,ALP of treatment group after treatment were significantly lower than those of the control group (P <0.05) ; after 4 weeks of treatment,the total effective rate was 82.14% in treatment group,60.87% in the control group,it was significantly higher in treatment group than that in the control group,the difference was statistically significant between two groups (x2 =11.102,P < 0.05).After treatment,the immune indexes of two group were significantly decreased.All immune indexes lower were significantly better in treatmat group than those in the control group (P < 0.05).Conclusion UDCA combined with Magnesium isoglycyrrhizinate in treatment of patients with primary biliary cirrhosis can significantly improve the clinical symptoms,improve clinical efficacy,and adverse reactions were mild,so it can be considered as one of the methods of treatment of PBC.
作者 王晓伟
出处 《胃肠病学和肝病学杂志》 CAS 2014年第7期819-821,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 熊去氧胆酸 异甘草酸镁 原发性胆汁性肝硬化 免疫指标 UDCA Magnesium isoglycyrrhizinate Primary biliary cirrhosis Immune index
  • 相关文献

参考文献10

二级参考文献61

  • 1闫惠平,庄辉,刘燕敏,冯霞,檀玉芬,刘妍,张欣,赵春惠.原发性胆汁性肝硬化患者的免疫学特点分析[J].中华肝脏病杂志,2005,13(1):12-16. 被引量:49
  • 2徐伟,李志琴,吴少瑜,吴曙光.蛇毒解离素的结构特征及其与生物学活性的关系[J].中国药理学通报,2005,21(1):17-22. 被引量:10
  • 3雷丹青,周先丽,李映新.尖吻蝮蛇毒小分子多肽的分离及抗血小板聚集作用[J].中国药理学通报,2006,22(9):1126-1129. 被引量:14
  • 4Vasiliy Ivanovich Reshetnyak.Concept on the pathogenesis and treatment of primary biliarycirrhosis[J].World Journal of Gastroenterology,2006,12(45):7250-7262. 被引量:11
  • 5Kaplan MM,Poupon R.Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol.Hepatology,2009,50:652.
  • 6Hirschfield GM,Liu X,Xu C,et al.Primary biliaiy cirrhosis associated with HLA,IL12A,and IL12RB2 variants.N Engl J Med,2009,360:2544-2555.
  • 7Yoshida K,Yang GX,Zhang W,et al.Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type Ⅱ mice.Hepatology,2009,50:1494-1500.
  • 8Lleo A,Selmi C,Invernizzi P,et al.Apotopes and the biliary specificity of primary biliary cirrhosis.Hepatology,2009,49:871-879.
  • 9Rong G,Zhong R,Lleo A,et al.Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis.Hepatology,2011,In press.
  • 10Lleo A,Bowlus CL,Yang GX,et al.Biliary apotopes and anti-mito-chondrial antibodies activate innate immune responses in primary biliary cirrhosis.Hepatology,2010,52:987-998.

共引文献84

同被引文献62

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部